CF
SNTI icon

Cantor Fitzgerald’s Senti Biosciences Holdings SNTI Stock Holding History

Cantor Fitzgerald’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,197
Closed -$118K – 432
2021
Q4 		$118K Buy
+1,197
New +$119K 0.01% 301

Other funds holding SNTI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Cantor Fitzgerald's SNTI Position: Q1 2022 in Review

Cantor Fitzgerald sold out of Senti Biosciences Holdings (SNTI) in Q1 2022, closing a stake of 1,197 shares — an estimated $118K sold.

Cantor Fitzgerald first reported a position in SNTI in Q4 2021 and held it in 1 quarter. The position peaked at $118K in Q4 2021. 45 funds tracked by Wall St. Rank hold SNTI as of Q1 2022.

  • Cantor Fitzgerald reported no remaining Senti Biosciences Holdings position as of Q1 2022 after selling out during the quarter.
  • Cantor Fitzgerald sold 1,197 Senti Biosciences Holdings shares in Q1 2022, an estimated $118K.
  • Cantor Fitzgerald first reported a position in Senti Biosciences Holdings in Q4 2021 and held it in 1 quarter.
  • Cantor Fitzgerald's Senti Biosciences Holdings position peaked at $118K in Q4 2021.
  • 45 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q1 2022.

Based on Cantor Fitzgerald's 13F filing for Q1 2022, filed 16 May 2022.